A Phase 1 Study of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Body Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic Cancer
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Carboplatin (Primary) ; Gemcitabine (Primary)
- Indications Gynaecological cancer
- Focus Adverse reactions; Biomarker; Pharmacogenomic
- 04 Aug 2015 Biomarkers information updated
- 25 Jul 2013 Planned End Date changed from 1 Aug 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 07 Mar 2013 Planned end date changed from 1 Feb 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.